GSK asks to consolidate Zofran lawsuits; Prescriptions in England up 3.3% in 2014 thanks to Viagra, diabetes meds;

@FiercePharma: Got an idea for an FDA drug study? Send an email. Editor's corner | Follow @FiercePharma

@EricPFierce: Our Twitter chat is less than an hour off. Don't miss the discussion on #sustainedrelease with BASF expert Thorsten Cech. @BASF_Pharma | Follow @EricPFierce

@CarlyHFierce: Roche's MS hopeful will amp up payer pricing pressure, analyst says. Article | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) has asked a federal judicial panel to consolidate a dozen lawsuits alleging that its antinausea medication Zofran can cause birth defects. More

> Bloodthinners, antidepressants, diabetes drugs and Viagra helped the number of prescriptions dispensed in England rise 3.3% last year. Report

> Eisai's epilepsy treatment Fycompa has launched in the U.K. Report

> In Israel, life sciences upstarts are struggling to follow the lead of local generics giant Teva ($TEVA). Story

> U.K. Chancellor George Osborne has committed to increasing NHS funding by £8 billion a year. More

> Pet pharmaceuticals group Dechra says its revenue for the year is up by about 10%. More

Medical Device News

@FierceMedDev: ICYMI yesterday: Mindray down on the acquisition of remainder of Chinese orthopedics company for $72.6M. Article | Follow @FierceMedDev

@EmilyWFierce: JAMA: Mammography does not reduce breast cancer deaths, could result in overdiagnosis. Story | Follow @EmilyWFierce

> Theranos signs its first health insurer in a deal with Capital BlueCross. More

> Device makers to offer stronger guarantees on products if they fail to perform. Story

Biotech News

@FierceBiotech: Who should make this year's Fierce 15? Nominate the most promising private biotechs. Nomination form | Follow @FierceBiotech

@JohnCFierce: Novartis says Entresto will be priced at $12.50 a day. More | Follow @JohnCFierce

@DamianFierce: Entresto, described by $NVS CEO Joe Jimenez as a "multi-blockbuster," is now approved to treat heart failure. More | Follow @DamianFierce

> Sanofi advances a one-shot malaria program as drug resistance spreads. Article

> AstraZeneca, Ironwood score PhIII success in China. Item

Biotech Research News

> UC San Diego accuses USC of conspiring to grab Alzheimer's research, funding. Report

> Computer scientists warn about the coming tsunami of genomics data. News

> Falsely accused 'Rambo' protein actually guards against heart failure. More

> UCSD researchers point to promising new drug target for glioblastoma. Story

> Researchers launch PhI study to test new approach to T cell immunotherapy. Article

Diagnostics News

> Theranos nabs FDA clearance for finger-stick herpes test. More

> BG Medicine gets FDA blessing for automated chronic heart failure test. Report

> Natera bags $180M in IPO to ramp up R&D. News

> Epic Sciences and LabCorp expand global reach with Asia clinical trials deal. Story

> Quest and Quintiles rev up new lab testing JV. Article

Pharma Marketing News

> Roche's MS hopeful will amp up payer pricing pressure, analyst says. News

> Bydureon, Invokana, Xarelto brand teams shelled out most to doctors in 2014. Article

> Merck, Samsung rack up data on Humira biosim, setting stage for approval apps. More

> Pfizer's Viagra first ED drug available in single-dose packets. Story

> Early Avycaz sales could signal bigger payoff for superbug-fighting antibiotics. Report

And Finally... CVS Health ($CVS) is withdrawing its membership from the U.S. Chamber of Commerce after media reports that the trade group was lobbying globally against antismoking laws. News

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.